<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">PROPAFENONE</span><br/>(pro-pa'fen-one)<br/><span class="topboxtradename">Rythmol<br/></span><b>Classifications:</b> <span class="classification">cardiovascular agent</span>; <span class="classification">antiarrhythmic classic</span><br/><b>Prototype: </b>Flecainide<br/><b>Pregnancy Category: </b>C<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>150 mg, 225 mg, 300 mg tablets</p>
<h1><a name="action">Actions</a></h1>
<p>Class IC antiarrhythmic drug with a direct stabilizing action on myocardial membranes. Reduces spontaneous automaticity.</p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Appropriate dose and concentration decreases rate of single and multiple PVCs. In addition, suppresses ventricular tachycardia.
         Exerts a negative inotropic effect on the myocardium.
      </p>
<h1><a name="uses">Uses</a></h1>
<p>Ventricular arrhythmias.</p>
<h1><a name="unlabeleduses">Unlabeled Uses</a></h1>
<p>Atrial tachyarrhythmias, reentrant arrhythmias, Wolff-Parkinson-White syndrome.</p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Uncontrolled CHF, cardiogenic shock, sinoatrial, AV or intraventricular disorders (e.g., sick sinus node syndrome, AV block)
         without a pacemaker; bradycardia, marked hypotension; bronchospastic disorders; electrolyte imbalances; hypersensitivity to
         propafenone; nonlife-threatening arrhythmias; chronic bronchitis, emphysema; lactation.
      </p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>CHF, AV block; hepatic/renal impairment; older adult patients; pregnancy (category C). Safety and efficacy in children are
         not established.
      </p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Ventricular Arrhythmias</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> Initiate with 150 mg q8h, may be increased at 34 d intervals (max: 300 mg q8h)<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1>
<ul>
<li>Dosage increments gradually are usually made with older adults or those with previous extensive myocardial damage.</li>
<li>Significant dose reduction is warranted with severe liver dysfunction. Consult physician.</li>
<li>Store at 15°30° C (59°86° F).</li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">CNS:</span>
<span class="speceff-common">Blurred vision, dizziness,</span> paresthesias, fatigue, somnolence, vertigo, headache. <span class="typehead">CV:</span> Arrhythmias, ventricular tachycardia, hypotension, bundle branch block, AV block, <span class="speceff-life">complete heart block</span>, sinus arrest, CHF. <span class="typehead">Hematologic:</span> Leukopenia, granulocytopenia (both rare). <span class="typehead">GI:</span> Nausea, abdominal discomfort, constipation, vomiting, dry mouth, <span class="speceff-common">taste alterations,</span> cholestatic hepatitis. <span class="typehead">Skin:</span> Rash. 
      <h1><a name="interactions">Interactions</a></h1><span class="typehead"> Drug:</span>
<b> Amiodarone,</b>
<b>quinidine</b> increases the levels and toxicity of propafenone. May increase levels and toxicity of <span class="classification">tricyclic antidepressants</span>, <b>cyclosporine,</b>
<b>digoxin,</b>
<span class="classification">beta blockers</span>, <b>theophylline,</b> and <b>warfarin</b> may increase levels of both <b>propafenone</b> and <b>diltiazem.</b>
<b>Phenobarbital</b> decreases levels of propafenone. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Absorption:</span> Readily absorbed from GI tract. <span class="typehead">Peak:</span> 3.5 h. <span class="typehead">Distribution:</span> 97% protein bound, highest concentrations in the lung. Crosses placenta, distributed into breast milk. <span class="typehead"> Metabolism:</span> Extensively metabolized in the liver. <span class="typehead">Elimination:</span> 18.538% of dose excreted in urine as metabolites. <span class="typehead">Half-Life:</span> 58 h. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Monitor cardiovascular status frequently (e.g., ECG, Holter monitor) to determine effectiveness of drug and development of
            new or worsened arrhythmias.
         </li>
<li>Monitor patients with preexisting CHF closely for worsening of this condition. Monitor for digoxin toxicity with concurrent
            use, because drug may increase serum digoxin levels.
         </li>
<li>Report development of second- or third-degree AV block or significant widening of the QRS complex. Dosage adjustment may be
            warranted.
         </li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Report to physician any of following: Chest pain, palpitations, blurred or abnormal vision, dyspnea, or signs and symptoms
            of infection.
         </li>
<li>Be aware when taking concurrent warfarin of possible increase in plasma levels that increase bleeding risk. Report unusual
            bleeding or bruising.
         </li>
<li>Monitor radial pulse daily and report decreased heart rate or development of an abnormal heartbeat.</li>
<li>Be aware of possibility of dizziness and need for caution with walking, especially in older adult or debilitated patients.</li>
<li>Do not breast feed while taking this drug.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>